Category: Gene Therapy Pipeline

  • Lexeo Acquires Stelios to Expands its Gene Therapy Pipeline for Rare Cardiovascular Diseases

    Shots: Lexeo acquires exclusive rights to three preclinical AAV-mediated gene therapy programs for the treatment of rare cardiac disorders, focused on TNNI3-associated HCM & ARVC The acquisition will complement and bolster LEXEO’s advanced pre-clinical gene therapy pipeline with the addition of three novel programs for rare cardiac diseases Additionally, preclinical results from the TNNI3-associated HCM […]